NDNingning Dong

Ningning Dong

*This is an algorithmically generated author record based on publicly available information.

Ningning Dong has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Budong Zhu

    Peking University Cancer Hospital and Institute

    1 shared publication
  • Chao-Ying Wang

    School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Guohong Song

    Peking University Cancer Hospital and Institute

    1 shared publication
  • Hanfang Jiang

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology Peking University Cancer Hospital & Institute Beijing China

    1 shared publication
  • Jing Yu

    Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai

    1 shared publication
  • Jun Jia

    Department of Oncology, Dongguan Institute for Clinical Cancer Research, Affiliated Dongguan People's Hospital, Southern Medical University, 3 Wandao Road South, Dongguan, 523059 Guangdong, China

    1 shared publication

Latest Publications

  • Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine

    by Ningning Dong, Jing Yu, Chaoying Wang, Xiaohui Zheng, Zheng Wang, Lijun Di, Guohong Song, Budong Zhu, Li Che, Jun Jia, et al.

    Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC. 79 SNPs in CYP450, whose minor allele frequency were ≥10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson’s χ2 test or Fisher’s exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes. There is no significant association between polymorphisms and both objective response and OS. Only one SNP, CYP1A1 rs1048943 A>G (Ile462Val), was significantly associated with PFS (P = 0.0003). Multivariate analysis confirmed its prognostic significance for PFS (P = 0.004). CYP1A1 rs1048943 A>G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients. However, confirmatory study is needed to validate this finding.